Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Guizhounli Pharmaceutical Co's Net Margin % or its related term are showing as below:
SHSE:603439'
s Net Margin % Range Over the Past 10 Years
Min: 2.72 Med: 14.99 Max: 17.9
Current: 2.91
SHSE:603439's Net Margin % is ranked worse than 58.11% of 962
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs SHSE:603439: 2.91
Guizhounli Pharmaceutical Co (SHSE:603439) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Guizhounli Pharmaceutical Co Net Margin % Related Terms
Guizhounli Pharmaceutical Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Guizhounli Pharmaceutical Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guizhounli Pharmaceutical Co Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Guizhounli Pharmaceutical Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Guizhounli Pharmaceutical Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guizhounli Pharmaceutical Co (SHSE:603439) has a Net Margin % of 11.63% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Guizhounli Pharmaceutical Co and its competitors. This is 22% below median its historical median of 14.99. Over the past decade, Guizhounli Pharmaceutical Co's Net Margin % has ranged from 2.72 to 17.90. According to the industry distribution chart, Guizhounli Pharmaceutical Co ranks #559 out of 962 companies in the Drug Manufacturers industry, placing it in the top 58.1%.
Is Guizhounli Pharmaceutical Co's Net Margin % too high?
Guizhounli Pharmaceutical Co's current Net Margin % of 11.63% is 22% below median its 10-year median of 14.99. Over the past 10 years, this metric has ranged from a low of 2.72 to a high of 17.90. The Drug Manufacturers industry median Net Margin % is 5.56. Guizhounli Pharmaceutical Co's value of 11.63% is 109.2% above this industry median. Based on the distribution chart, Guizhounli Pharmaceutical Co ranks #559 out of 962 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Guizhounli Pharmaceutical Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guizhounli Pharmaceutical Co's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Guizhounli Pharmaceutical Co ranks #559 out of 962 companies for Net Margin %. This places Guizhounli Pharmaceutical Co in the lower half of its industry. The industry median Net Margin % is 5.56. Guizhounli Pharmaceutical Co's value of 11.63% is 109.2% above this benchmark. Historically, Guizhounli Pharmaceutical Co's own Net Margin % has ranged from 2.72 to 17.90 over the past decade. While the company's 10-year median is 14.99 vs. the industry median of 5.56, Guizhounli Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guizhounli Pharmaceutical Co's current Net Margin % of 11.63% is 109.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Guizhounli Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guizhounli Pharmaceutical Co's current Net Margin % is 11.63%, which is 22% below median its own 10-year median of 14.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guizhounli Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Guizhounli Pharmaceutical Co (SHSE:603439) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥14.70, compared to a current price of ¥11.14 — trading 24.2% below its estimated fair value. The current Net Margin % is 11.63%, which is 22% below median its 10-year median of 14.99 and 109.2% above the Drug Manufacturers industry median of 5.56. Guizhounli Pharmaceutical Co's overall GF Score™ is 90/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Guizhounli Pharmaceutical Co (SHSE:603439), the current Net Margin % is 11.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guizhounli Pharmaceutical Co (SHSE:603439) Overvalued in 2026?
Based on GuruFocus' analysis, Guizhounli Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥11.14 is trading 24.2% below its estimated GF Value™ of ¥14.70.
GuruFocus considers Guizhounli Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:603439:
Net Margin %: 11.63% (22% below median its 10-year median of 14.99)
GF Value™: ¥14.70 vs. price of ¥11.14 (24.2% below fair value)
Industry Position: 109.2% above the Drug Manufacturers median (#559 of 962)
No single metric tells the full story. See the SHSE:603439 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guizhou Sanli Pharmaceutical Co Ltd is engaged in Chinese pharmaceutical research, development, production and marketing. The company produces and sells soft capsules, hard capsules, sprays (including Chinese medicine extraction) and provides Chinese medicine science and technology consulting services. Its products include Pediatric medication; Respiratory system medication; Cardiovascular and cerebrovascular drugs; Digestive medicine; Trauma injury medication; Rehabilitation medicine; and Ophthalmic medicine.
90GF Score
Get the complete analysis for SHSE:603439
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603439 has been successfully added to your 
